Analysts Set Seres Therapeutics, Inc. (NASDAQ:MCRB) Price Target at $13.20

Seres Therapeutics, Inc. (NASDAQ:MCRB – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the five analysts that are presently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold rating and four have issued a buy rating on the company. The average twelve-month target […]

Related Keywords

Canada , ,Royal Bank ,Coppell Advisory Solutions ,Bridgefront Capital ,Seres Therapeutics Inc ,Nasdaq ,Raymond James Associates ,Seres Therapeutics Company Profile ,Seres Therapeutics ,Get Free Report ,Marketbeat Ratings ,Therapeutics Stock Down ,Advisory Solutions ,Get Free ,Seres Therapeutics Daily ,Nasdaq Mcrb ,Mcrb ,Medical ,Ratings ,Consensus ,